LILRB1 and B-cell chronic lymphocytic leukemia: CFSE-stained PBMCs obtained from 11 CLL patients were treated with anti-ILT2 blocking antibody alone or in combination with lenalidomide for 14 days, and the effect on the proliferation of NK cells was determined by flow cytometry analysis (Figure 6A).